<DOC>
	<DOCNO>NCT01720212</DOCNO>
	<brief_summary>To evaluate safety plasma concentration change YM178 single- repeated-administration oral absorption control tablet healthy Chinese subject .</brief_summary>
	<brief_title>Study Assess Safety Plasma Concentration YM178 OCAS Tablet ( Mirabegron ) Healthy Chinese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Mirabegron</mesh_term>
	<criteria>1 . Body Mass Index ( BMI ) 19 24 , weight less 50 kg . 2 . Good health status 3 . The female subject must either postmenopausal surgically sterile . All woman child bear potential require use adequate contraception , must lactate , must breastfeed . 1 . The subject know suspected hypersensitivity test drug constituent formulation use . 2 . Drug abuser alcoholic . 3 . The subject consume alcohol within 36 hour administration . 4 . The subject positive hepatitis B surface antigen ( HBs Ag ) hepatitis C virus ( HCV ) antibody . 5 . The subject positive human immunodeficiency virus ( HIV ) . 6 . The subject consumes 1L tea coffee per day . 7 . Smokers . 8 . The subject donate lose 200 mL blood 9 . The subject participate clinical trial 10 . The subject take drug prototype main metabolite completely eliminate 11 . The subject take drug repeatedly may affect metabolism test drug 12 . Psychopath .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>YM178</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>OCAS</keyword>
	<keyword>Chinese Healthy Volunteers</keyword>
	<keyword>PK</keyword>
	<keyword>Safety</keyword>
</DOC>